Gelonghui on March 7 丨 Xianju Pharmaceutical (002332.SZ) announced that Zhejiang Cuize Pharmaceutical Technology Co., Ltd. (“Cuize Pharmaceutical”) is a shareholding company of Zhejiang Xianju Pharmaceutical Co., Ltd., and the company holds 41.6501% of its shares. Recently, the company received a notice that Cuize Pharmaceutical plans to introduce investors to increase its registered capital. The registered capital is to be increased from 137.255.24 million yuan to 15.7019.53 million yuan, and the registered capital is 19.76.429 million yuan. The capital increase price is 36.43 yuan/share. Based on actual business conditions, the company plans to relinquish Cuize Pharmaceutical's priority subscription rights for this capital increase.
The following nine investors will participate in this capital increase: Fortune Berry No. 2 (Tianjin) Venture Capital Partnership (limited partnership), Zhejiang Xianju Yongsheng Industry & Trade Co., Ltd., Shenzhen Hi-Tech Investment Venture Capital Co., Ltd., Chengdu Shenzhen Hi-Tech Investment SME Venture Capital Fund Partnership (limited partnership), Shenzhen Shenrong Ruihe Venture Capital Partnership (limited partnership), Mao Yiping, Cai Haiying, Wang Baojun, Zheng Xufen. All subscribers who intend to participate in the capital increase invested a total of RMB 72 million in cash to subscribe for Cuize Pharmaceutical's additional registered capital of RMB 1,776.429 million. After the capital increase was completed, the company's shareholding ratio in Cuize Pharmaceutical dropped from 41.6501% to 36.4076%.